Infinimmune

Infinimmune announced $75M in Series A financing on August 11, 2026. Infinimmune raised a $75 million Series A co-led by Regeneron Ventures and Playground Global to advance human-derived antibody programs in atopic dermatitis and inflammatory disease.

Round details

The financing includes backing from Regeneron Ventures, Playground Global, RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Merck Global Health Innovation Fund, Everbright Biofund. The company did not publish a valuation with the announcement.

• Round: Series A
• Capital announced: $75M

How the company plans to use the capital

The financing will accelerate clinical development of Infinimmune’s two lead programs in atopic dermatitis, support advancement of additional programs leveraging human-first biology, and enable continued deployment of its Anthrobody discovery platform.

Why this matters for GTM teams

The round was co-led by Regeneron Ventures and Playground Global, with existing investors Merck Global Health Innovation Fund and Everbright Biofund also participating.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Infinimmune Series A announcement.